价差近70倍被问询，挂网药品价格治理纵深推进

Core Insights - The article highlights the ongoing efforts in drug price governance in China, particularly focusing on the scrutiny of drug prices in the context of centralized procurement and regulatory measures [1][2][8] Group 1: Regulatory Actions - Yunnan Medical Insurance Bureau issued an inquiry regarding the pricing of a specific drug, indicating that the price of the oral solution of Enalapril Maleate by Sichuan Baili Pharmaceutical is significantly higher than similar products, with a price difference of nearly 70 times [3][4] - The inquiry requires the company to justify the pricing structure, including factory price, terminal price, and sales expenses, as well as to address potential issues of price inflation through agents [3][4] Group 2: Market Context - The oral solution of Enalapril Maleate is primarily used for treating hypertension and heart failure, and it was first approved in the U.S. in 2016, with a domestic version launched in 2022 [4][5] - The original drug's price is reported to be approximately 4611.71 yuan per bottle, while the domestic versions are priced around 558 yuan, indicating a significant markup in the market [4][5] Group 3: Price Governance Mechanisms - The Chinese government has implemented a series of measures to regulate drug prices, including centralized procurement and the establishment of a national monitoring price list for drugs [8][9] - The new pricing governance mechanism aims to promote transparency and discourage unethical practices such as kickbacks and monopolistic behaviors, encouraging companies to focus on product quality and innovation [9][10] Group 4: Industry Impact - The ongoing price governance efforts are expected to lead to a more standardized pricing system across provinces, with many regions already implementing local rules for drug pricing [9][10] - The article notes that several companies have begun to voluntarily adjust their prices in response to regulatory pressures, indicating a shift towards more competitive pricing in the pharmaceutical industry [9][10]